Abstract
Aims
To determine the effects on quality of life after starting insulin with, or switching
to, insulin analogue therapies in the 24-week, prospective, non-interventional, observational
A1chieve study conducted across four continents in people with type 2 diabetes.
Methods
Health-related quality of life (HRQoL) was assessed at baseline and at 24 weeks by the validated EQ-5D questionnaire (visual analogue score [VAS] and five dimensions)
in 66,726 people who had started using basal insulin detemir, mealtime insulin aspart
(with or without a basal insulin) or biphasic insulin aspart 30.
Results
For the overall cohort, reported HRQoL increased significantly by 13.8 points from
63.4 points at baseline to 77.2 points at 24 weeks (p < 0.001) (scale 1–100, 100 = best health imaginable). Beginning or changing insulin was associated with a significant
increase in HRQoL score (+15.0 points and +11.1 points, respectively), resulting in
a similar score at 24 weeks in the two populations (77.8 and 75.9 points). Reported HRQoL also increased
statistically significantly in people administering any insulin analogue regimen and
across all regions, although there were some marked regional differences in reported
HRQoL at baseline.
Conclusion
Compared with baseline scores, beginning insulin with, or switching to, insulin analogue
therapies are associated with increased HRQoL.
Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Diabetes Research and Clinical PracticeAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Quality of life and diabetes.Diabetes Metab Res Rev. 1999; 15: 205-218
- Addressing barriers to initiation of insulin in patients with type 2 diabetes.Primary Care Diabetes. 2010; 4: S11-S18
- Multivariate models of health-related utility and the fear of hypoglycaemia in people with diabetes.Curr Med Res Opin. 2006; 22: 1523-1534
- Overcoming psychological barriers to insulin use in type 2 diabetes.Clin Cornerstone. 2006; 8: S19-S26
- Psychological insulin resistance in patients with type 2 diabetes: the scope of the problem.Diabetes Care. 2005; 28: 2543-2545
- Overcoming patient barriers to initiating insulin therapy in type 2 diabetes mellitus.Clin Cornerstone. 2007; 8: 33-40
- Management of type 2 diabetes with multiple oral hypoglycaemic agents or insulin in primary care: retrospective cohort study.Br J Gen Pract. 2007; 57: 455-460
- Impact of improved glycemic control on quality of life in patients with diabetes.Endocr Pract. 2004; 10: 502-508
- Newer agents for blood glucose control in type 2 diabetes: systematic review and economic evaluation.Health Technol Assess. 2010; 14: 1-248
- The A1chieve study: a 60 000-person, global, prospective, observational study of basal, meal-time, and biphasic insulin analogs in daily clinical practice.Diabetes Res Clin Pract. 2010; 88: S11-S16
- EuroQol—a new facility for the measurement of health-related quality of life.Health Policy. 1990; 16: 199-208
- Comparison of biphasic insulin aspart 30 given three times daily or twice daily in combination with metformin versus oral antidiabetic drugs alone in patients with poorly controlled type 2 diabetes: a 16-week, randomized, open-label, parallel-group trial conducted in Russia.Clin Ther. 2007; 29: 2374-2384
- Quality of life as a key indicator of patient satisfaction and treatment compliance in people with type 2 diabetes mellitus in the IMPROVE study: a multicentre, open label, non-randomised, observational trial.J Indian Med Assoc. 2009; 107: 464-470
- The safety and efficacy of biphasic insulin aspart 30 (BIAsp 30) in Iranians with type 2 diabetes: an open-label, non-randomised, multi-centre observational study—the Iran subgroup of the IMPROVE™ study.Endokrynol Pol. 2010; 61: 364-370
- Initiation of insulin glargine in patients with Type 2 diabetes in suboptimal glycaemic control positively impacts health-related quality of life. A prospective cohort study in primary care.Diabet Med. 2011; 28: 1096-1102
Barendse S, Singh H, Frier BM, Speight J. The impact of hypoglycaemia on quality of life and related patient-reported outcomes in type 2 diabetes: a narrative review. Diabet Med, in press.
- The use of the EQ-5D preference-based health status measure in adults with Type 2 diabetes mellitus.Diabet Med. 2011; 28: 395-413
Bradley C, de Pablos-Velasco P, Parhofer KG, Eschwège E, Gönder-Frederick L, Simon D. PANORAMA: a European study to evaluate quality of life and treatment satisfaction in patients with type-2 diabetes mellitus—study design. Primary Care Diabetes doi:10.1016/j.pcd.2011.04.004, in press.
Article info
Publication history
Accepted:
October 13,
2011
Received in revised form:
October 10,
2011
Received:
September 20,
2011
Footnotes
☆Grant support: The A1chieve study was funded by Novo Nordisk.
☆☆Clinical trial registration: Clinicaltrials.gov, NCT00869908.
Identification
Copyright
© 2011 Published by Elsevier Inc.
